Browse the evidence

Semaglutide showed a favorable hepatic safety profile with no discontinuations due to liver enzyme elevations.

Semaglutide can be considered safe for liver health in the studied population.

Subgroup analyses did not suggest differences in outcomes based on diabetes status or GLP-1 receptor agonist used.

GLP-1 RAs can be considered safe for use in diverse patient populations without increased risk of suicidality.

The estimated health care cost offsets from clinical benefits of GLP-1RAs are projected to be $18.2 billion over 10 years.

Practitioners should consider the potential health care savings from clinical benefits of GLP-1RAs.

GIP accounts for 60% to 80% of the postprandial insulin response.

Understanding GIP's role can help in managing postprandial insulin levels.

GIP is overexpressed in obese individuals, which may exacerbate insulin resistance.

Addressing GIP levels may be important in treating obesity-related insulin resistance.

Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02).

Clinicians should monitor for NAION in patients treated with semaglutide.

Current evidence remains insufficient to establish definitive conclusions regarding the association of semaglutide with NAION.

Further research is needed to clarify the risk of NAION with semaglutide.

GLP-1RA users had a lower risk of dementia (HR, 0.63; 95% CI, 0.50-0.81) compared to other antidiabetic drug users.

Practitioners may consider GLP-1RAs as a treatment option for reducing dementia risk in this population.

The screening criteria for sarcopenic obesity include BMI, waist circumference, calf circumference, the SARC-F, and the Finger Ring test.

These criteria can guide practitioners in screening for sarcopenic obesity.

Current hypertension guidelines do not yet recommend incretin-based therapies as first-line treatment because no large-scale trial has used blood pressure reduction as its primary endpoint, despite robust secondary data showing efficacy.

You cannot currently get GLP-1 medications prescribed specifically for high blood pressure as a first-line treatment under standard insurance guidelines. They are primarily approved for diabetes and weight loss. However, if you have both hypertension and obesity/diabetes, your doctor may prescribe them for those conditions, which will incidentally lower your blood pressure significantly.

Novel GLP-1-based therapeutics are rapidly advancing and may reshape the future landscape of obesity and type 2 diabetes treatment.

Practitioners should consider the potential of these novel agents in treating obesity and type 2 diabetes.

Triple agonists such as retatrutide target GIP, GLP-1, and glucagon receptors to amplify metabolic effects.

Consider the potential of triple agonists in enhancing metabolic outcomes for patients.

Common cardiovascular conditions, such as heart failure with preserved ejection fraction, can be conceptualized as a consequence of accelerated aging.

Understanding the link between aging and heart failure can guide prevention and management strategies.

NN1706 lowers body weight & improves glycemic control in obese rodents and monkeys.

NN1706 may also be beneficial for weight management and glycemic control in animal models of obesity.

Increased heart rate was observed across NN1706 treatment cohorts.

Clinicians should monitor heart rate in patients receiving NN1706 treatment.

Challenges with GLP-1s include side effects, nutritional deficiencies, and low long-term adherence.

Clinicians should be aware of and manage these challenges when prescribing GLP-1s.

Gender, household size, and education were associated with GLP-1 use and interest.

Marketers should consider demographic factors when targeting potential GLP-1 consumers.

Persistence in the OMM-eligible cohort was 73.8%.

High persistence rates suggest good adherence to tirzepatide among eligible patients.

Real-world evidence suggests slower tirzepatide dose escalation than in clinical trials.

Practitioners may need to adjust expectations regarding dose escalation in real-world settings.

Obesity is projected to affect approximately half the US population by the year 2035.

Practitioners should be aware of the increasing prevalence of obesity for public health planning.

Human body weight is physiologically regulated and maintained within a relatively narrow range in most mammals, including humans.

Understanding body weight regulation can inform strategies for managing obesity.

Difficulties in achieving body weight loss and maintenance in obese subjects are partly due to physiological regulatory systems that resist weight loss.

Recognizing these physiological challenges can guide effective weight loss strategies.

Obesity is a global epidemic and a significant public health challenge.

Recognize obesity as a critical issue in public health.

Current anti-obesity medications (AOMs) include gastrointestinal lipase inhibitors, nutrient-stimulated hormone-based therapies, and emerging multi-receptor agonists.

Consider these AOMs in obesity treatment strategies.